111 (YI) Fundamentals 2026 — Revenue Analysis | SniperIQ
111 (YI) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of
111 (YI) has a market capitalization of approximately
111 runs a net profit margin of -0.7%, a gross margin of 5.7%, and an operating margin of -0.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
111 reported revenue of ¥12.2B for fiscal year 2025, with net income of -¥17M and earnings per share (EPS) of -7.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
111 does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
111 carries a debt-to-equity ratio of -0.38x and a current ratio of 1.08x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For 111 (YI) the key facts are: market cap
Get 111's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.